| Thursday, November 16, 2017 |
Ultragenyx Pharmaceutical, Audentes Therapeutics, Fulcrum Therapeutics, Global Genes, and Springboard Enterprises have partnered to produce a three-day interactive workshop to address available options and actionable strategies with parties interested in advancing solutions to rare diseases.
The workshop will offer an overview of strategies for initiating a drug development company, one-on-one guidance, and peer discussions. Session topics include sources of capital and investor presentations, clinical and regulatory strategy, corporate legal and IP, and financing.
Intellectual Property partner Mark Hayman and associate Christina MacDougall will speak on a panel focused on: